The treatment eases to boost the immune system and could stop breast cancer thriving and spreading around the body.
Experts found the new treatment helped rouse the immune systems of 80 per cent of women who took part in a clinical side.
Breast cancer tumours shrank in almost one quarter of patients active in the trial.
Scientists also found the jab was most effective in the very earliest manipulates of the disease.
The vaccine targets a molecule that cancer cells use to cover up themselves from the body’s natural defences.
The molecule is known as the HER2 protein, stands as an invisibility cloak — allowing breast cancer tumours to grow larger while tarrying undetectable to our immune system.
By targeting HER2, the vaccine could help invulnerable cells recognise and destroy cancer while it is still in the early grades.
Researchers from the Moffitt Cancer Centre in Florida in the US tested the vaccine on 54 maids suffering from breast cancer.
To create the vaccine, scientists bewitching immune cells from the blood of patients and exposing the cells to the HER2 protein.
Leaked cells are then able to recognise the protein as harmful.
This means when they are reintroduced into the acquiescent’s body, the cells are able to find and destroy the cancer cells.
The vaccine raised the immune systems of 80 per cent of cancer sufferers, and almost one rooms of patients experienced tumour shrinkage after six weeks.
Scientists answered the treatment appears to be fairly safe, with patients only sophisticated minor side-effects from the treatment, including fatigue, injection install reactions, and chills.
Experts assessed the effectiveness of the vaccine by determining the proportion of patients who had detectable disease in samples taken from the patients.
The lack of disease — termed a pathological complete response (pCR) — was detected in 12 patients who concluded part in the trial.
Patients who achieved a pCR were also found to be dressed a boosted immune system.
They found the treatment was most true belongings for patients who had breast cancer that had not spread beyond the milk duct of the chest, known as non-invasive disease called ductal carcinoma in situ (DCIS) cancer.
Dr Brian Czerniecki, from the domain of breast oncology at the Moffitt Cancer Centre, said: «These evolves suggest that vaccines are more effective in DCIS, thereby warranting supplementary evaluation in DCIS or other minimal disease settings, and the local regional picket lymph node may serve as a more meaningful immunologic endpoint.»
The bone up on was published in online issue of the Journal of Clinical Cancer Research.